hronic infection with hepatitis C virus (HCV) may lead to liver failure and hepatocellular carcinoma. Current treatment for HCV includes high systemic doses of interferona (IFNa), which is effective in less than half of patients and may have severe side effects. We designed conditional IFNa and IFNg expression constructs to be triggered by HCV-induced activation of NFkB, and delivered these using highly efficient recombinant Tag-deleted SV40-derived vectors. NFkB activates the HIV-1NL4-3 long terminal repeat (HIVLTR) as a promoter, which accounts for the conditional transgene expression. Human hepatocyte lines and primary rat hepatocytes (PRH) were transduced with SV[HIVLTR](IFN) vectors, and transfected with HCV cDNA. Production of human and murine IFNa and IFNg in cytosol and culture supernatants was measured. HCV activated the HIVLTR to produce and secrete IFNs, and did so largely through the NFkB binding sites of the HIVLTR. Levels of IFNs secreted, and the magnitude of induction in response to HCV, were greater in hepatocyte lines than in primary cultured hepatocytes. However, even in the latter, supernatant IFNa concentrations achieved by this approach were similar to therapeutic serum concentrations sought in systemic IFNatreated patients. In coculture studies, secreted IFNa activated its cognate response elements in untransduced cells, suggesting that its potential inhibitory effects on HCV may not be limited to transduced cells. Although HCV replication in culture is difficult to assess, HCV-induced IFNa production demonstrably reduced HCV transcription. Conditional expression of IFNs within the liver may represent an attractive approach to therapy of severe chronic HCV infection that could avoid the side effects of systemic treatment regimens.
Introduction
The interferons (IFN) are a family of proteins formally divided into types I and II. The former (including IFNa and IFNb), of which there are several isoforms, are produced by most cell types in response to virus infection and other stimuli. The latter (also called IFNg) is mainly made by T lymphocytes and is important in activating certain T-cell and NK responses. Although IFNg is an effective antiviral and antineoplastic agent, its therapeutic effectiveness has been limited by the high systemic toxicity of systemically administered recombinant IFNg protein.
Recombinant human IFNa (rhIFNa) is less toxic, and is approved in the US for treatment of chronic hepatitis C virus (HCV) infection. In combination with ribavirin, rhIFNa is administered intensively to patients with progressive liver damage due to chronic hepatitis C. 1 This approach is effective in controlling the progression of chronic HCV infection in slightly less than half of patients. 2 Among the reasons for treatment failure are the short half-life of rhIFNa in the blood, the necessity of maintaining high blood levels of rhIFNa in order to achieve therapeutic levels in the liver, unpleasant or toxic side effects, viral resistance to rhIFNa that is associated with certain HCV genotypes, and the impermanence of the therapeutic effect in many cases if therapy is interrupted prematurely. 3, 4 An approach to treatment in which cDNAs for IFNs a and IFNg are delivered directly to the liver, that is the therapeutic target, could theoretically magnify the local therapeutic effect without requiring high systemic levels or repeated administration of the toxic and short-lived proteins. Thus, gene delivery to the liver might potentially be an adjunct to current therapies. For such liverdirected gene therapy to be effective, a large number of hepatocytes should be transduced, the DNA delivered must remain in these cells indefinitely, and, if possible, expression of IFN should respond to the presence of the offending virus but otherwise be quiescent.
For these studies, we used recombinant gene delivery vectors derived from Tag-deleted simian virus-40 (rSV40 s). For gene delivery to the liver, rSV40 vectors have been shown to deliver enduring transgene expression to very high percentages of unselected hepatocytes, whether resting or dividing, in vitro or in vivo. 5, 6 The goal of rendering transgene expression responsive to the presence of the offending HCV virus was approached by exploiting the reported ability of the HCV gene product NS5a to activate the cellular transcription factor NFkB, 7 as well as the known responsiveness of the promoter activity of the HIV-1 long terminal repeat (LTR) to NFkB. 8 Accordingly, we engineered rSV40 vectors to carry the HIVLTR as a promoter, to drive expression of murine and human IFNa and IFNg as transgenes. The effectiveness of HCV in activating these constructs to produce and secrete the several IFNs was tested, as was the ability of the IFNs so generated to activate paracrine signaling through IFNsignal response elements (ISRE) and the effect of IFN on detectable HCV transcript.
Results

HCV-induced expression of IFN delivered by SV[HIVLTR]IFN
Our strategy for these studies entailed transducing cells with SV[HIVLTR](IFN) vectors, then transfecting them with HCV cDNA to examine first the effectiveness of the transfected HCV cDNA in activating HIVLTR promoter activity. We then evaluated the effectiveness of the SV[HIVLTR](IFN) vectors in inhibiting HCV. These vectors were constructed as described previously 9 and in Materials and methods. A map of a generic vector such as an SV[HIVLTR](IFN) vector, is shown in Figure  1a . The HCV cDNA-carrying plasmid used in these studies is shown in Figure 1b .
This strategy relies upon the ability of transfected HCV cDNA to be transcribed upon transfection into liver cells. Normally, the HCV genome is transcribed as a single mRNA encoding a polyprotein that is subsequently post-translationally cleaved into its several substituents. 10 We therefore transfected HepG2 cells with the HCV cDNA construct and tested for its transcription using nested RT-PCR, with both sets of PCR primers chosen to amplify the NS5a region of this transcript, as described in Materials and methods. We found that transfection of HCV cDNA results in its transcription, . In all of these constructs, the HIV-1 LTR from HIV-1NL4-3 was used as a promoter to drive expression of the IFN cDNA in question. The LTR is positioned just 3 0 (counter-clockwise) to the SV40 early promoter (SV40-EP). Since it overlaps the SV40 origin of replication (ori), the SV40-EP must be retained intact in order to produce these vectors. To block transcription from it, four tandem polyadenylation signals (mpA) were inserted. The SV40 capsid genes (VP1, VP2, and VP3) and regulatory sequences are included in these vectors (enh¼enhancer; ses¼SV40 encapsidation signal), but are not expressed. (b) Structure of plasmid pRC/CMV-HCV, containing full genomic cDNA form of HCV, strain 1b, under the control of cytomegalovirus immediate-early promoter (CMV-IEP).
HCV-activated conditional expression vectors
AA Matskevich and DS Strayer and documented that the observed PCR product was derived from the transcribed HCV mRNA (Figure 2 ). Sequence analysis of this RT-PCR product was performed (not shown), and documented that the amplicand was in fact the appropriate part of the coding sequence for NS5a. In order to evaluate the potential therapeutic utility of rSV40-delivered, HIVLTR-driven IFN expression, we tested the time course of responsiveness to HCV transfection of IFN production and secretion by cells transduced with these constructs. Thus, HepG2 cells were transduced with SV[HIVLTR](IFN) constructs, then transiently transfected with HCV cDNA. IFN production was measured by ELISA in cell lysates and in culture supernatants. Although the specific IFN levels and kinetics of responsiveness to HCV varied among the different IFNs, transfection of the HCV genome into transduced cells significantly increased IFN, both intracellularly and secreted into culture media, as a function of time (shown in Figure 3 for mouse IFNa) (CmIFNa). The peak production and secretion of IFN induced by transient transfection with HCV cDNA occurred 2-3 days post-transfection.
HCV activation of HIVLTR occurs via NFkB binding sites in the HIVLTR
It has been reported that HCV NS5a activates NFkB, which, in turn, is known to activate the HIVLTR as a promoter. 7, 8 Figure 4 for hIFNa). HCV activated wtHIVLTR to cause the cells to produce and secrete hIFNa. Production and secretion of hIFNa was comparable in cultures transduced with SV[wtHIVLTR](hIFNa) but without transfected HCV cDNA, in cultures transduced with SV[muHIVLTR](hIFNa) with or without transfected HCV cDNA, and in untransduced cultures. Cultures that had been treated with SV[wtHIVLTR](hIFNa) þ HCV cDNA consistently produced greater amounts of IFN, and secreted it at much higher levels than did any of the control groups: at the minimum Po0.05 for all comparisons between SV[wtHIVLTR](hIFNa) þ HCV and all other groups. These data are further illustrated by the time course studies shown in Figure 3, Culture supernatants and cell lysates were also analyzed by Western blotting, using antisera specific for the individual IFNs. Figure 6 shows the representative studies from cultures transduced with rSV40 vectors carrying mIFNg as a transgene. In both cell lysates and culture supernatants, the 21 kDa mIFNg protein was mainly detected in cultures that had been both trans- 
Frequency of IFN-producing cells
The transduction efficiency with rSV40 vectors in unselected cultures is generally 498%. 9 In order to We also asked if prior transduction with an rSV40 vector altered the transfection efficiency of transduced cells. That is, we asked whether the differences in IFN expression among the various study and control groups might represent differences in the success of the secondary transfection step that followed transduction. Accordingly, HepG2 cells were transduced with SV[wtHIVLTR](IFN), SV[muHIVLTR](IFN) or SV(BUGT), or mock-transduced. They were then transfected with pCMVluc, respectively carrying enhanced green fluorescent protein and luciferase as reporter genes. There was no significant difference in luciferase activity ( Figure 8 ) between any of the experimental groups (P40.1), indicating that transduction did not produce significant differences in transfection efficiency. These data were confirmed by quantitation of fluorescent cells on cotransfection with pT7egfp (data not shown).
Effectiveness of SV[HIVLTR](IFN) activation by HCV in primary hepatocytes
In the light of these results achieved using a hepatoblastoma cell line, we asked if SV[HIVLTR}(IFN) vectors would show comparable responsiveness to HCV in primary hepatocytes. Accordingly, PRH were cultured from normal rat livers, and transduced with the IFNcarrying vectors. Cultures were then 'challenged' by transfecting HCV cDNA, and intracellular and secreted IFN concentrations were measured by ELISA (shown in Figure 9 for mIFNa).
Although levels of IFN made by primary hepatocytes in response to HCV were lower than were seen using HepG2 cells, similar patterns of responsiveness to HCV were evident. That is, liver cells that had been transduced with SV[wtHIVLTR](mIFNa) and transfected with HCV produced and secreted more mIFNa than did mock-treated cultures, cultures transduced similarly but not transfected with HIV, or cultures transduced with SV[muHIVLTR](mIFNa). The relative magnitudes of these differences are comparable to those seen in the experiments described above. Differences between groups receiving SV[muHIVLTR](mIFNa) þ HCV and all other groups were highly significant: at the least, Po0.05 for all such comparisons.
The efficiency of transfection of these primary hepatocytes was about 5%, as observed using pCMV-eGFP plasmid ( Figure 10a ). Furthermore, the morphology of these cells was not appreciably altered by transduction þ transfection ( Figure 10b ).
Secreted, HIVLTR-driven IFNa activates signaling in a paracrine fashion in untransduced cells
An important part of the antiviral activity of IFNs is their ability to activate cellular signaling pathways, which alter transcription of a number of genes. At the same time, since all hepatocytes in vivo would probably not be transduced with the IFN-carrying vector, it was important to establish whether IFN produced by cells that were both transduced with the SV[HIVLTR](IFN) vector and infected with HCV would secrete enough IFN to exert paracrine -possibly protective -effects on neighboring In parallel, similar cells were transfected with pISRE-Luc, which carries the IFN-signal response element, driving the reporter gene luciferase. On the fourth day after HCV challenge, the pISRE-Luc-transfected cells were added to the cultures and the luciferase activity that was stimulated by the IFNa made by the transduced cells was measured. In these studies (Figure 11a ), luciferase activity in response to IFNa made by cells that were transduced and challenged was substantially higher than in mocktransduced cultures. This increase was consistent and statistically significant (minimum significance for all such comparisons Po0.05).
An additional series of studies tested culture supernatants from transduced, HCV-challenged primary hepatocytes or HepG2 cells. These supernatants were 
Discussion
The development of new strategies to manage chronic hepatitis C remains a major goal for the treatment of HCV-infected individuals. In this report, we describe a potential approach to HCV therapy using gene delivery to provide expression of IFNa and IFNg, in order to protect hepatocytes from HCV infection and replication. IFNa and IFNg exert antiviral activities via several different mechanisms. One of their principal effects is to inhibit protein synthesis. Thus, IFNa is produced in response to virus entry into the cell, possibly as a result of the activation of protein kinase R (PKR) by doublestranded viral RNAs (dsRNAs). [11] [12] [13] The expression of one IFN, induced in this fashion, may upregulate expression of other IFNs via receptor-mediated signaling pathways.
14,15 Viral dsRNAs also activate 5 0 -oligoadenylate synthetases (OAS), which in turn activate an enzyme that degrades 18S and 28S ribosomes, RNase L. 16 Activated PKR phosphorylates and so inactivates eucaryotic translation initiation factor 2 (eIF2a). 17, 18 Both activation of RNase L and inactivation of eIF2a inhibit virus replication by decreasing production of viral (and cellular) proteins.
It has been reported that one or more signal transduction pathways, beginning with viral dsRNA, activate transcription of IFNa and IFNb, which in turn signal their abilities to inhibit virus infection and replication via a cognate receptor. [19] [20] [21] [22] This receptor, on binding these type I IFNs, activates the Jak-STAT signaling cascade, to upregulate transcription of an array of cellular genes. [23] [24] [25] These IFNs have important effects on the immune system: they alter expression, activation, and localization of many cellular proteins, including MHC-I and -II, and TNFa, that activate and execute antiviral T and NK cell responses. 26 IFNa also stimulates Th1 responses to such Th1-tropic cytokines such as IL-12, IL-15, and IL-18, and mediates T-cell responses to IL-12-induced secretion of IFNg. 26, 27 IFNg is generally made and secreted by activated T and NK lymphocytes. [28] [29] [30] It mediates many immune functions, and is important in activating cytotoxic responses against virus-infected cells. IFNg also possesses antiviral activities that are mechanistically similar 19 Owing to their potent effects on the immune system and on virus infections, as well as inhibitory effects on cell proliferation, IFNs have been tested as therapy for viral, neoplastic, and other diseases. rhIFNg, tried in this mode, was far too toxic to be useful when administered systemically. 33 rhIFNa is used effectively not only as therapy for viral illnesses such as hepatitis C, but also for several malignancies, particularly certain types of leukemia, myeloma, and some solid tumors that are otherwise resistant to drug therapies, such as malignant melanoma and renal cell carcinoma. 34 Although systemically administered rhIFNa is less toxic than systemic rhIFNg, treatment regimens using either have significant drawbacks in addition to toxicity. These include the need to maintain high blood concentrations of the recombinant protein in order to provide adequate therapeutic levels at disease sites, and uneven distribution of the proteins outside of the circulatory system. 20 Gene delivery could conceivably address these limitations, including the toxic side effects (especially of IFNg) by allowing localized gene delivery to the liver, and by making IFN expression responsive to the presence of the offending virus. Thus we sought to provide the potential for permanent, HCV-responsive IFN expression at the site where the IFN is needed, without having to maintain comparable levels throughout the body. Gene delivery would be accomplished using rSV40 vectors, which are very efficient in permanently transducing hepatocytes in vitro and the liver in vivo.
We also report the use of HIV-1 LTR as an HCVresponsive promoter, to drive expression of IFNs. 6, 35 The potential utility of HIVLTR as a promoter that could be activated by HCV was first tested using plasmid cotransfection with HCV cDNA þ reporter plasmids incorporating HIVLTR driving either luciferase or chloramphenicol acetyl transferase. These studies (not shown) suggested that transducing with SV[HIVL-TR](IFN), followed by transient transfection with HCV cDNA, might demonstrate effective gene delivery and IFN induction by HCV. Studies reported here repeatedly demonstrated that rSV40-delivered, HIVLTR-driven IFNs (IFNa and IFNg) are produced and secreted in response to the presence of HCV.
The incremental production and secretion of IFNs, as shown by ELISA, was generally 2-to 5-fold, compared to mock-transduced cells, or to cells that were transduced with SV[HIVLTR](IFN) but not transfected with HCV. Relative levels of IFN were comparable in all ELISAs, whether the transgenes were human or murine, and whether they were IFNa or IFNg. The levels of IFN (eg IFNa) secreted in these studies are comparable to therapeutic levels for chronic HCV infection. The value of the ELISAs for these studies was their adaptation to testing the large numbers of samples generated, and their reproducibility and comparability to externally supplied quantitation standards. However, they carried the potential for detecting immunologically cross-reactive proteins besides the IFNs being tested. This possibility is underscored by the Western blotting studies, which demonstrated some cross-reactivity with other proteins. Our Northern analyses, which were performed under conditions of very high stringency, showed that virtually the only detectable IFN expression occurred in cells that had been both transduced with SV[wtHIVLTR](IFN) and challenged by transfection with HCV cDNA.
HIVLTR-driven gene expression is controlled by numerous cell regulatory proteins that interact with cis- HCV-activated conditional expression vectors AA Matskevich and DS Strayer acting sequences located in the HIV-1LTR. Among the multiple regulatory elements of the HIV-1 LTR, the kB enhancer, which contains two copies of kB elements at nucleotides 104-81, is considered the main inducible cisacting element, 36 and therefore our study was mainly focused on NFkB-mediated activation. Deletion or sitedirected mutations of this regulatory sequence may affect LTR transcriptional activation induced by T-cell activation stimuli and by HIV Tat protein. [36] [37] [38] It has been widely demonstrated that the kB enhancer element binds and responds to NFkB/Rel family of transcription factors, which are induced by a number of stimuli such as mitogens, cytokines, and specific T-cell activators. 39 The core promoter region of the HIV-1 LTR also contains three tandem Sp1-binding sites located upstream of the TATA box. These Sp1-binding sites are necessary for basal and Tat-induced transcriptional activity. 40 Other transcription factors such as AP-1, or ATF-1 can activate HIV replication deleted in these Sp1 sites. 41, 42 Members of the NF-AT family of transcription factors also bind an overlapping but distinct sequence at the kB enhancer: NF-AT2 (also called NF-ATc) cooperates with NFkB and Tat in HIV-1 LTR transcriptional activation. 43 These data may also help to explain why wtHIVLTR and muHIVLTR could be active in the absence of the direct NFkB activator (HCV) in some situations.
The responsiveness of IFN to HCV was expected to reflect the ability of HCV NS5a to activate NFkB, 7 which in turn would upregulate HIVLTR as a promoter. 8 We did not directly address the mechanism of HCV activation of NFkB, but we found that mutating NFkB binding sites in the HIVLTR eliminated HCV responsiveness in IFN production and secretion. Detectable IFN made by cells treated with SV[muHIVLTR](IFN) þ HCV was comparable to levels seen in negative control cells and supernatants. Thus, these studies support the responsiveness of HIVLTR promoter activity to HCV, via NFkB.
Although the transcriptional activity of the HIVLTR was strongly, consistently and significantly activated by HCV in all studies, some leakiness of the wt HIVLTR was observed. This may reflect HCV activation of other transcription factors, as indicated above. Thus, additional optimization of the HIVLTR as a promoter is desirable, and is underway, to avoid such low level increases in its HCV-independent transcriptional activation.
Although NFkB has been shown to be activated by a large number of stimuli, our data suggest relatively specific responses to HCV. Transcriptional activation of the HIV-1 LTR via NFkB has also been described for other viruses, such as herpes simplex virus type-1, cytomegalovirus, human T-cell leukemia virus, and human herpesvirus 8. [44] [45] [46] [47] Therefore, in HIV carriers, disease progression may be directly influenced by coinfection with multiple viruses. Results presented here thus suggest that there may be complex interactions between HCV and HIV-1 replicative cycles, and that HCV may be a cofactor for HIV disease progression. Thus, the identification of HIVLTR as an HCV-responsive promoter is a potentially important advance in considering gene therapy of hepatitis C, but may also offer insight into the effects of the frequently observed coinfection of AIDS patients with HCV.
It should be noted in this context that SV[HIVL-TR](IFN) strongly inhibits HIV. 9 At the same time, since not all hepatocytes would be transduced by the rSV40 vector, it was important to understand whether IFNs produced by cells that were both transduced with rSV40 and infected with HCV were likely to protect cells that were not transduced, should the latter come into contact with HCV. Thus, we tested IFNs made by transduced and transfected cells for their ability to elicit detectable signaling via IFN receptors in naive neighboring cells. Levels of ISRE activation by IFNs produced by SV[HIVL-TR](IFN)-transduced, HCV-transfected cells were consistently 25-50% greater than levels seen in control cells.
Since ISRE are activated by a variety of cellular transcription factors, many of which are not specific for IFN-signaled responses, it is not surprising that background ISRE activities seen in these studies were high. Thus, although such studies do not establish that naive cells would be protected, they suggest that the rSV40-delivered IFN response to HCV has paracrine effects on neighboring cells, via ISRE.
It is difficult to study HCV challenge in tissue culture (or, even, in experimental animals). For this reason, we delivered HCV to HepG2 human hepatoblastoma cells and to PRH by transfecting HCV cDNA. The effect we sought was production of HCV proteins, in particular HCV-activated conditional expression vectors AA Matskevich and DS Strayer
NS5a
. As attempts to demonstrate NS5a or other HCV proteins by immunostaining or Western blotting using commercial antibodies gave equivocal results (data not shown), we tested HCV transcription by in situ RT-PCR. Cells adherent to coated slides were used to visualize those cells in which HCV cDNA transfection elicited an HCV RNA. We were able determine that between 5 and 10% of cells in transfected cultures expressed HCV transcript detectably. In cultures transduced with SV[HIVLTR](IFN), and then transfected with HCV cDNA, the percentage of cells expressing the IFN protein as detected by immunostaining was comparable (E5-10%). Thus, the transduction efficiency approached 100%, and the limiting factor in determining how many cells produced IFN was the transfection efficiency of HCV cDNA.
The amounts of IFN produced and secreted should be judged in this context: HepG2 cells secreted about 50 pg IFN/day and primary hepatocytes about 20 pg IFN/day. Lower production of IFN in primary cells may reflect differences in levels, or accessibility to activation, of NFkB in transformed versus primary cells in response to HCV. Lower transfection efficiency for PRH than for HepG2 cells may also reflect the fact that about 20% of hepatocytes are naturally binucleate, which might affect transduction by rSV40 vectors. 48 The levels of IFN measured reflected IFN secretion by only 5-10% of cells in the culture -those cells that were also transfected with HCV. Had delivery of HCV been more effective, much more IFN secretion would probably have been observed.
Inhibition of HCV transcription was demonstrated by the semiquantitative approach of comparing the numbers of cells making detectable HCV transcript as visualized by in situ RT-PCR. These studies showed that the IFNa delivered by SV[HIVLTR](mIFNa), and elicited by HCV, decreased detectable HCV transcript in PRH. Although this is not a precise simulation of HCV infection in people, it provides a reasonable assessment of the efficacy of the IFN expressed in those hepatocytes in inhibiting HCV, since HCV does not replicate well in cultured cells.
Recombinant gene transfer vectors derived from SV40 virus (rSV40) are not subject to many of the problems that have limited gene delivery using other vector systems. rSV40s are made at a very high titers and infect -and so transduce -almost all nucleated cell types very efficiently, regardless of lineage or whether they are resting or dividing; they integrate and are not susceptible to transgene silencing. 35 They also elicit no detectable immune response by normal animals and so can be used to deliver multiple transgenes over time and in sequence. [49] [50] [51] The ability of rSV40 vectors to deliver long-term transgene expression to mostly quiescent liver cells has been illustrated in murine models, in vivo: immunochemical staining carried out 7 weeks after administration of SV(BUGT) showed that X60% of hepatocytes continued to express the BUGT transgene. 6 Expression continued undiminished for X18 months. 51 IFNa has proven to be therapeutically efficacious in many cases of HCV infection. Our data suggest that SV[HIVLTR](IFNa), perhaps in combination with SV[HIVLTR](IFNg), may deliver IFN expression that responds to HCV and so may be useful in the treatment of HCV infection.
Materials and methods
Cell lines
The human hepatoblastoma cell line, HepG2, was pathogen and PPLO-free, and was maintained in Dulbecco's modified Eagle's medium (DMEM) þ 2 mM L-glutamine, 2 mM nonessential amino acids, 1 mM sodium pyruvate, streptomycin (100 mg/ml), penicillin (200 U/ml), and 10%(v/v) bovine calf serum (NCS, Hyclone).
Freshly isolated PRH were grown in William's medium E, supplemented with 10% (v/v) bovine calf serum, streptomycin (100 mg/ml), penicillin (200 U/ml), gentamicin (10 mg/ml), 0.015 U insulin/ml, and 2 mM dexamethasone.
All these cells were cultivated on rat type-1 collagentreated plates.
COS-7 cells, used to package rSV40 vectors, were maintained in DMEM as described above.
Plasmids
A cDNA form of HCV, strain 1b, complete virus genome as pRC/CMV-HCV, was the kind gift of Dr Mark Feitelson (Department of Pathology, TJU) ( Figure 1 ). rSV40 vectors were made by cloning the transgene of interest (7specific promoter) into a plasmid-carried modified SV40 genome. 52, 53 The production of SV[wtHIVLTR](IFNa) has been reported in the context of inhibition of HIV replication in lymphocytes. 9 The other SV[HIVLTR](IFN) constructs were made similarly. Thus, the IFN cDNAs and the wt or mutant (doubly mutated at its NFkB binding sites, so as to destroy NFkB binding (muHIVLTR)) HIVLTRs were cloned into pT7(DD) mpa. This plasmid carries an SV40 genome in which the Tag gene was replaced by a polylinker upstream of the SV40 polyadenylation site. Transcription from the SV40 early promoter (which overlaps the ori, and so cannot be deleted) is blocked by multiple tandem polyadenylation signals. All structures were verified by automated DNA sequencing (PE Applied Biosystems, Inc., Kimmel Cancer Center, TJU).
rSV40 vectors
Construction of recombinant SV40 derivative viruses (rSV40) for gene transfer has been described previously. 54 Briefly, rSV40 genomes were excised from the modified pT7blue (Novagen) carrier plasmid, gel purified, recircularized, and transfected into COS-7 cells. These cells supply all packaging functions in trans. Replicationincompetent vectors are isolated from COS-7 cell lysates, purified by ultracentrifugation and titered by in situ PCR, as described. Typical infectious titers for vectors prepared in this manner are between 10 12 and 2 Â 10 13 infectious units (IU)/ml. 41 The rSV40 vectors used for these studies were named according to the promoter (wt or mutant HIVLTR, the IFN type and its species of origin). The specificity of the transfection with HCV was confirmed by nested PCR. The PCR was performed on the extracted RNA using the Rneasy Mini Kit (Qiagen, MA, USA) utilizing outer set of primers for the first round. The reaction mixture contained RT buffer (Invitrogen single step RT PCR kit) (50 mM Tris-HCl, 75 mM KCl, 1.5 mM MgCl 2 ) containing 10 mM dithiothreitol, 200 U of Superscript II Reverse transcriptase (Invitrogen), 40 U of RNase inhibitor (RNAsin; Pharmacia), 300 mM each dGTP, dATP, dCTP, 5 U of platinum Taq polymerase (Invitrogene), and 0.2 mM of each primer. The extracted RNA (5 ml) was added to the mix. As a control, RNA was treated with 40 U of DNase (Promega) or 10 U of RNase One (Promega). The PCR was performed over 25 cycles, the first one consisting of 30 min at 581C, followed by 25 cycles of 1 min at 941C, 1 min at 601C, and 1 min at 721C, and finally 7 min at 721C. The first round of product (5 ml) was added to 45 ml of PCR mix containing 1 Â buffer, 300 mM each dNTP, 2.5 U of platinum Taq polymerase, and 0.2 mM of inner set of primers. Thermocycling was performed over 25 cycles, each consisting of 1 min at 941C, 1 min at 601C, and 1 min at 721C.
Detection of HCV RNA by in situ RT-PCR
HepG2 cells were spread on chamber, fixed in sterile saline, resuspended in ice-cold 10% buffered formaldehyde solution and kept for 2 h at 371C and treated with Proteinase K at 371C for 10 min, washed again and treated with 40 U of DNase (Invitrogen) for 4 h, at 371C. As a control, cells were treated with 40 U of RNase. Permeabilized HepG2 cells were then washed in PBS and treated by RT buffer (Invitrogen single step RT PCR kit) (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl 2 ) containing 10 mM dithiothreitol, 200 U of Superscript II Reverse transcriptase (Invitrogene), 40 U of RNase inhibitor (RNAsin; Pharmacia), 1 mM each dGTP, dATP, dCTP and 1 mM of dUTP-FITC, platinum Taq polymerase and 50 pmol of the outer oligonucleotide primers of HCV. The tubes were incubated at 581C for 45 min and at 941C for 5 min to inactivate residual RT activity. The RT step was followed by first round PCR: 35 cycles of 1 min each at 94, 58 and 721C, with the final extension done at 721C for 10 min. At the end of RT-PCR, slides were incubated in PBS protected from light until the coverslips were removed. Slides were washed in 0.1 Â SSC at 371C for 15 min, then analyzed under epifluorescence microscope for FITC emission.
IFN pathway reporter plasmid
To elucidate the activation of IFN-inducible Elements (ISRE) reporter plasmid ISRE-Luc, containing luciferase reporter gene driven by a basic promoter element (TATA box) plus five repeats of ISRE cis-enhancer element (Stratagene, La Jolla, CA, USA), was purchased.
All cloned plasmids were purified using the Qiaquick plasmid kit (Qiagen, Hilden, Germany). Nucleotide sequencing of constructed plasmids was confirmed by using an autosequencer (PE Applied Biosystems) and the standard dye termination.
Transduction and transfection experiments
For transduction with SV40-derived virus, HepG2 or PRH were treated once at an MOI of 100, as described. After 5 days, cells were transfected with 7.5 mg HCVcDNA-containing plasmid (Lipofectamine 2000, Invitrogen), according to the manufacturer's instructions, and then were cultured for 2-3 days.
Culture medium and cells were collected 48 h posttransfection. Cells were lysed on ice in 300 ml of lysis buffer (50 mM TRIS, pH 7.4/150 mM NaCl/1% Nonidet P-40/1% sodium deoxycholate/1 Â protease inhibitor mix (Sigma)/0.5 mM sodium orthovanadate/0.02% sodium azide) for 5 min. Cell extracts was analyzed for luciferase activity and IFN expression.
Luciferase activity
Luciferase activity was measured using the Steady-Glo Luciferase Assay System (Promega), according to the manufacturer's instructions.
Determination of IFN by ELISA
Expression of all the IFNs was measured using their respective IFN ELISA kits (Antigenix America). This kit detects IFN using a sandwich immunoassay. In this assay, plates are coated with monoclonal antibodies against the particular IFN. Binding to that antibody was detected using an anti-secondary antibody conjugated to horseradish peroxidase (HRP). Tetramethyl-benzidine was used as a substrate to quantitate the antigenantibody complex by subsequent color development.
Western blot analysis
6
HepG2 cells either SV[HIVLTR]IFN-transduced, mock-transduced or expressing HBsAg or BUGT and subsequently transfected with HCV (if mentioned) were washed in PBS. Cells were lysed on ice in 300 ml of lysis buffer (50 mM TRIS, pH7.4/150 mM NaCl/1% nonidet P-40/1% sodium deoxycholate/1 Â protease inhibitor mix (Sigma)/0.5 mM sodium orthovanadate/0.02% sodium azide) for 5 min. Cell culture medium was concentrated two times using Centricon-100 concentrators (Amicon, Bedford, MA, USA).
Equal amounts of protein were separated by 4-20% gradient Tris-glycine SDS/PAGE (Bio-Rad) and transferred to a PVDF-Plus membrane (Osmonics, Minnetonka, MN, USA). After overnight blocking (PBS (pH 7.4)/ 0.1% Tween-20 containing 5% nondry milk), blots were incubated with monoclonal anti-IFN antibody (Antigenix America) (1:400) in PBS (pH 7.4)/0.1% Tween-20 containing 5% nondry milk) for 1 h at room temperature. Goat anti-mouse IgG conjugated to HRP (Pierce) (1:10 000) was added, and blots were incubated for 1 h at room temperature. Each antibody incubation was followed by three extensive washes in PBS (pH 7.4)/0.1% Tween-20. Detection was by chemiluminescence (ECL Plus, Amersham) according to the manufacturer's instruction.
Northern blot analysis
Total RNA from 10 6 HepG2 cells either SV[HIVLTR]IFNtransduced, mock-or SV-BUGT-transduced and subsequently transfected with HCV (if mentioned) was extracted using the RNA easy Mini Kit (Qiagen, CA, USA). Samples of 15 mg of total RNA were electrophoresed in a 1% agarose/formaldehyde gel, transferred on a nylon filter (Nytran Super Charge, Schleicher and Schuell), UV cross-linked with a Stratalinker oven (Stratagene) and baked for 2 h at 801C in a vacuum oven. Filters were prehybridized in 50% formamide, 5 Â SSPE, 20 mg/ml denatured salmon sperm DNA, 5 Â Denhardt's solution, 0.1% SDS at 421C for 8 h, then hybridized under the same conditions with an IFN cDNA probe that had been labeled with a 32 P-dCTP using a random priming labeling kit (Gibco BRL). Hybridization was performed at 421C in 2 Â SSC overnight. After hybridization, filters were washed under high stringency conditions in 0.1 Â SSC, 0.1% SDS at 37-551C for 30 min and signals were visualized using a phosphoimager (Molecular Dynamics Storm 840). To assess loading of various lanes, Northern blots were stripped and reprobed with a radiolabeled cDNA for human b-actin. 
Statistical analysis
IFN levels and luciferase activity in HepG2 and PRH cells from various treatment groups and controls at various time points were compared by the Student's ttest or analysis of variance. Levels of statistical significance between the test group, on the one hand, and the several control groups, on the other, varied considerably. In each figure, the minimum level of statistical significance is mentioned (usually, Po0.05), but often comparisons between test and control groups typically reached much higher levels of significance (eg Po0.001 or better).
